Bourgeon Capital Management Boosted By $348,600 Its Fireeye (FEYE) Position; Last Week Alnylam Pharmaceuticals, Inc. (ALNY) Analysts

May 24, 2018 - By Peter Kolinski

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Bourgeon Capital Management Llc increased Fireeye Inc (FEYE) stake by 84.69% reported in 2017Q4 SEC filing. Bourgeon Capital Management Llc acquired 24,900 shares as Fireeye Inc (FEYE)’s stock rose 17.58%. The Bourgeon Capital Management Llc holds 54,300 shares with $771,000 value, up from 29,400 last quarter. Fireeye Inc now has $3.18B valuation. The stock increased 1.11% or $0.185 during the last trading session, reaching $16.855. About 1.97 million shares traded. FireEye, Inc. (NASDAQ:FEYE) has risen 34.55% since May 24, 2017 and is uptrending. It has outperformed by 23.00% the S&P500.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 107 analyst reports since August 7, 2015 according to SRatingsIntel. On Tuesday, July 11 the stock rating was maintained by Cowen & Co with “Buy”. The rating was maintained by Piper Jaffray on Wednesday, September 20 with “Buy”. The rating was downgraded by Leerink Swann on Thursday, October 6 to “Mkt Perform”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Hold” rating given on Friday, May 4 by Stifel Nicolaus. The firm earned “Market Perform” rating on Thursday, September 21 by Leerink Swann. As per Thursday, September 7, the company rating was reinitiated by Barclays Capital. The rating was maintained by Piper Jaffray on Monday, April 23 with “Buy”. The firm earned “Outperform” rating on Tuesday, August 11 by FBR Capital. The firm has “Buy” rating by Cowen & Co given on Thursday, September 7. Nomura maintained the stock with “Sell” rating in Friday, February 9 report. See Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) latest ratings:

07/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $118 New Target: $107 Maintain
04/05/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $160 New Target: $134 Maintain
04/05/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $107 New Target: $95 Maintain
23/04/2018 Broker: Piper Jaffray Rating: Buy New Target: $182.0000 Maintain
03/04/2018 Broker: JMP Securities Rating: Buy New Target: $207.0000 Maintain
28/03/2018 Broker: FBR Capital Rating: Buy New Target: $200.0000 Maintain
28/03/2018 Broker: Evercore Rating: In-Line New Target: $143 Initiates Coverage On
22/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $182.0 Maintain
13/03/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $151 New Target: $154 Maintain
12/03/2018 Broker: FBR Capital Rating: Buy New Target: $200.0 Maintain

Since February 16, 2018, it had 0 insider purchases, and 12 selling transactions for $6.68 million activity. Another trade for 3,190 shares valued at $55,336 was sold by Reese Travis M.. $55,337 worth of FireEye, Inc. (NASDAQ:FEYE) was sold by King Alexa on Wednesday, May 16. Robbins William T sold $261,121 worth of stock. Mandia Kevin R. sold 113,130 shares worth $1.83 million. $548,803 worth of FireEye, Inc. (NASDAQ:FEYE) was sold by VERDECANNA FRANK.

Among 34 analysts covering Fireeye Inc (NASDAQ:FEYE), 16 have Buy rating, 0 Sell and 18 Hold. Therefore 47% are positive. Fireeye Inc had 122 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank on Wednesday, August 2 with “Hold”. The firm has “Buy” rating by Stifel Nicolaus given on Monday, September 18. The rating was initiated by Goldman Sachs with “Neutral” on Monday, March 21. As per Friday, February 9, the company rating was maintained by Stephens. Morgan Stanley maintained the shares of FEYE in report on Wednesday, March 28 with “Overweight” rating. The rating was maintained by Evercore with “Buy” on Tuesday, August 1. Bank of America upgraded it to “Buy” rating and $18 target in Monday, March 20 report. The stock of FireEye, Inc. (NASDAQ:FEYE) earned “Market Perform” rating by BMO Capital Markets on Wednesday, August 2. The firm has “Buy” rating by Wunderlich given on Thursday, November 5. Imperial Capital downgraded it to “In-Line” rating and $15 target in Tuesday, August 9 report.

Investors sentiment decreased to 1.15 in Q4 2017. Its down 0.09, from 1.24 in 2017Q3. It dived, as 36 investors sold FEYE shares while 66 reduced holdings. 31 funds opened positions while 86 raised stakes. 116.96 million shares or 2.52% less from 119.98 million shares in 2017Q3 were reported. Blair William Com Il owns 71,560 shares. Tocqueville Asset Management Limited Partnership, a New York-based fund reported 773,925 shares. Moreover, Riverpoint Cap Limited Liability Co has 0.08% invested in FireEye, Inc. (NASDAQ:FEYE) for 88,990 shares. Virtu Ltd Limited Liability Company reported 52,448 shares or 0.04% of all its holdings. 218,386 are held by Hsbc Public Limited. Price T Rowe Associate Inc Md reported 48,310 shares. Advisory Svcs Limited Co stated it has 0.03% in FireEye, Inc. (NASDAQ:FEYE). The Virginia-based Wilbanks Smith & Thomas Asset Limited Liability Corp has invested 0.06% in FireEye, Inc. (NASDAQ:FEYE). Cibc World Markets reported 0% of its portfolio in FireEye, Inc. (NASDAQ:FEYE). Jpmorgan Chase And has 0.01% invested in FireEye, Inc. (NASDAQ:FEYE) for 2.83M shares. Geode Mngmt Lc holds 0.01% or 1.58 million shares in its portfolio. Pnc Finance Serv Group Inc has invested 0% in FireEye, Inc. (NASDAQ:FEYE). Ubs Asset Mngmt Americas Inc holds 0% of its portfolio in FireEye, Inc. (NASDAQ:FEYE) for 151,860 shares. Telemus Cap Ltd Liability Corporation invested 0% of its portfolio in FireEye, Inc. (NASDAQ:FEYE). Janney Montgomery Scott Limited Com holds 0% or 13,068 shares.

More important recent FireEye, Inc. (NASDAQ:FEYE) news were published by: Seekingalpha.com which released: “FireEye: Waiting For The Next Phase” on May 10, 2018, also Seekingalpha.com published article titled: “FireEye, Inc. 2018 Q1 – Results – Earnings Call Slides”, Seekingalpha.com published: “FireEye: The Turnaround Is On Track” on May 05, 2018. More interesting news about FireEye, Inc. (NASDAQ:FEYE) was released by: Seekingalpha.com and their article: “BMO raises FireEye target to 3% downside” with publication date: May 03, 2018.

Since January 4, 2018, it had 0 buys, and 10 selling transactions for $38.04 million activity. The insider Ausiello Dennis A sold 17,117 shares worth $2.57 million. 27,823 shares were sold by SCHIMMEL PAUL, worth $4.17 million. Shares for $2.24 million were sold by SHARP PHILIP A. Vaishnaw Akshay also sold $12.67 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares. $5.50M worth of stock was sold by Greene Barry E on Wednesday, March 14. KEATING LAURIE sold $234,033 worth of stock. Shares for $985,958 were sold by Greenstreet Yvonne.

Investors sentiment increased to 2.03 in Q4 2017. Its up 1.11, from 0.92 in 2017Q3. It is positive, as 27 investors sold Alnylam Pharmaceuticals, Inc. shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported. Clearbridge Invests Limited Liability, New York-based fund reported 2,516 shares. Moreover, Bluemountain Cap Mngmt Limited Liability Corporation has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 1,826 shares. The Ohio-based Gateway Investment Advisers Ltd has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Nomura Asset Mngmt Communication Limited owns 10,740 shares. Bnp Paribas Arbitrage owns 12,076 shares. Bb Biotech Ag holds 3.76% or 1.05M shares. Emerald Advisers Pa, Pennsylvania-based fund reported 14,863 shares. Price T Rowe Assoc Md invested in 0.25% or 12.23M shares. Voya Inv Management Limited Liability holds 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 30,388 shares. Amalgamated Bancorp holds 0.06% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 17,112 shares. Rhumbline Advisers holds 0.03% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 99,915 shares. Moreover, Tekla Mgmt Lc has 0.56% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 114,966 shares. State Of Wisconsin Invest Board accumulated 0.03% or 86,131 shares. Blue Ridge Capital Ltd Liability stated it has 1.34 million shares or 5.66% of all its holdings. California-based Parallax Volatility Advisers Lp has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” on May 17, 2018, also Seekingalpha.com with their article: “Alnylam Pharmaceuticals: Hitting The Next Growth Curve” published on April 25, 2018, Seekingalpha.com published: “Alnylam Pharmaceuticals (ALNY) Q1 2018 Results – Earnings Call Transcript” on May 04, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “Wave Life Sciences: What’s Cooking Behind This Innovator?” published on May 23, 2018 as well as Fool.com‘s news article titled: “Alnylam Looks Forward” with publication date: May 08, 2018.

FireEye, Inc. (NASDAQ:FEYE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>